Background: Most patients receiving therapy for acute myeloid leukemia (AML) enter an interval in which leukemic blast cells cannot be detected by light microscopy (i.e., morphologic remission). However, many of these patients experience a subsequent relapse. Multidimensional flow cytometry, which allows the discrimination of antigens expressed on normal and malignant cells, can detect small numbers of cancer cells in bone marrow or peripheral blood specimens. This technique enables the detection of one leukemic blast cell among 10 3 to 10
Techniques to detect residual cancer cells after the initiation of therapy have been developed for a variety of cancers. In patients with acute lymphoblastic leukemia, a relationship between residual disease and risk of subsequent relapse has been demonstrated by use of polymerase chain reaction-based methods that detect unique gene rearrangements characteristic of leukemic cells (/) . Detection of the t(15; 17) chromosomal abnormality by use of coupled reverse transcription and the polymerase chain reaction appears promising as a means of predicting clinical outcome for the small subset of patients with acute myelogenous leukemia (AML) who have acute promyelocytic leukemia (2) . However, the heterogeneity of cytogenetic abnormalities in the majority of AML cases precludes a more generalized use of this technique. Furthermore, since the fusion gene produced in t(8;21) AML persists many years following diagnosis during continuous hematologic remission (3, 4) , such a technique may not accurately identify patients with a greater risk of relapse.
Since cell surface antigen expression during normal development is carefully regulated, normal cells manifest characteristic antigenic patterns that are consistently observed in healthy individuals (5) . Leukemic cells demonstrate inappropriate antigen relationships that markedly vary from this normal pattern (6) (7) (8) (9) . Multidimensional flow cytometry (7, 9) exploits the differences between normal and abnormal cells to identify AML blast cells in heterogeneous bone marrow or peripheral blood specimens at times when such cells are either undetectable or difficult to distinguish from normal regenerating marrow precursors by light microscopy. In this approach, in addition to cell size and granularity, up to four fluorescent signals corresponding to the expression of various cell-surface anti-gens are measured simultaneously. By selecting a subgroup of cells with a particular array of forward-and right-angle light-scatter properties and display of leukocyte differentiation antigens, examination for leukemia can be limited to a discrete subpopulation of cells without the interference of normal regenerating hematopoietic cells.
Morphologic remission is defined as the presence of less than or equal to 5% blast cells by direct microscopic evaluation of a bone marrow aspirate. Hence, the sensitivity of this method is approximately 5 x 1CT 2 . Since the multidimensional flow cytometric assay can exclude normal lymphocytes, monocytes, and myeloid precursors from evaluation, aberrant leukemic phenotypes at levels as low as approximately 1CT 3 to 10~2 in an analysis of 30 000 nucleated cells can be detected (9, 10) . We employed multidimensional flow cytometric analyses to determine whether pediatric patients with AML who harbored identifiable residual leukemic cells during morphologic remission were more likely to experience overt leukemic relapse than those without detectable disease.
Patients and Methods

Study Patients
Fifty-one previously untreated pediatric patients with AML from the Children's Hospital of Philadelphia and the Children's Hospital and Medical Center in Seattle were selected for this study because previously cryopreserved diagnostic and remission bone marrow specimens were available for multidimensional flow cytometric analyses. Thirty-nine of these patients had entered morphologic remission and thus constituted the assessable study group. A total of 205 bone marrow specimens were obtained from the 39 patients at various intervals during therapy. A marrow specimen coincident with the achievement of first morphologic remission was available from 35 of these patients. Characteristics of this study group, treated between 1987 and 1994, are summarized in Table 1 . All six patients with French-American-British (FAB) M3 morphology were found to harbor the t( 15; 17) cytogenetic abnormality (and vice versa). Demographic and clinical information from 586 children with AML in whom morphologic remission was achieved in Childrens Cancer Group study 2891 was used to determine whether the 39 assessable patients accurately represented the larger AML treatment group as a whole. 
Cells and Cryopreservation
Bone marrow samples aspirated from the iliac crest were obtained in accordance with the Childrens Cancer Group treatment protocol's required observations. Specimens were obtained at diagnosis and following each course of induction or consolidation therapy. These samples were studied fresh (seven patients) or cryopreserved (32 patients). No notable clinical or demographic differences were identified between these subgroups. All specimens were separated by Ficoll-Hypaque density centrifugation (specific gravity, 1.077g/cm 3 ) (Pharmacia, Biotech, Inc., Piscataway, NJ). Cryopreserved cells were suspended in a mixture of 10% dimethyl sulfoxide (Sigma Chemical Co., St. Louis, MO) and 90% newborn calf serum (HyClone Laboratories, Inc., Logan, UT) and frozen in liquid nitrogen until immunophenotyping studies were performed.
Multidimensional Flow Cytometric Analysis
Cryopreserved bone marrow specimens were rapidly thawed at 37 'C, mixed with 5 mL phosphate-buffered saline (PBS) that was supplemented with 2% fetal calf serum (FCS) (BioWhittaker, Inc., Walkersville, MD), and washed twice with PBS-2% FCS at 37 'C. After determining cell number on a hemocytometer, the cell concentration of fresh or thawed specimens was adjusted to 1 x 10 cells/mL. The diluted cells (100 |iL) were mixed with 50 \iL of mixed pairs of fluorescein isothiocyanate-and phycoerythrin-conjugated monoclonal antibodies ( Table 2 ) that had been titered for maximum fluorescence in addition to a peridinin-chlorophylla-protein-conjugated antibody raised against CD45 (Becton Dickinson, San Jose, CA). The cells were incubated with the antibodies at room temperature for 15 minutes and then washed with PBS-2% FCS.
Samples were analyzed on a CytoronAbsolute (Ortho Diagnostic Systems, Inc., Raritan, NJ) or a FACScan (Becton Dickinson) flow cytometer. A total of 10 000-30 000 events was recorded for each combination of antibodies. Average specimen viability was 64% (median, 72%; range, 13%-91%). List mode data were analyzed with WinList software (Verity Software, Topsham, ME) in accordance with previously published techniques (11). Briefly, a computerized region was generated to limit analysis to only those intact cells with a forward and right-angle light-scatter pattern characteristic of lymphocytes, monocytes, maturing monocytoid or myeloid elements, and blast-sized cells. This gating eliminated residual dead cells, cellular debris, and granulocytes from the domain of interest The fluorescence intensity reflecting the differential expression of CD45 was plotted against side scatter for this enriched group of cells. From the resulting histogram, another smaller computerized region was generated to further limit subsequent analyses to the group of cells with side scatter and CD45 expression distinctive of myeloblasts. This combination of regions using Boolean logic helped to eliminate normal lymphocytes, monocytes, maturing myeloid elements, and normal lymphoblasts from the abnormal cells of interest. A final histogram quantitatively displayed the degree of cell-surface antigen expression reflected by fluorescence intensity from each of two additional monoclonal antibodies (Table 2) . From this highly refined Boolean subset of cells with a specific forward-and side-light scatter and characteristic CD45 expression, visual assessment for the constellation of antigens expressed by the diagnostic leukemia specimen was made and compared with the expected patterns of normal cells and with subsequent specimens for an individual patient (Fig. 1) . A bone marrow sample was defined as being multidimensional flow cytometric positive if a distinct cluster of blast-sized cells, present at a level exceeding 0.1 % of the total number of nucleated cells analyzed for that specimen, manifested aberrant antigen expression as defined by one or more of the following characteristics: 1) expression of nonmyeloid antigens, 2) asynchronous expression of myeloid-associated antigens, 3) overcxpression of myeloidassociated antigens, or 4) absence of expression of myeloid-associated antigens (7). Specimens with (15) 35 (90) 4(10) 5 (13) 22 (56) 12(31)# *Unless otherwise specified, values = number of patients.
tFrench-American-British morphology classification. tWBC = white blood cell. §DCTER regimen: daunorubicin, cytarabine, thioguanine, etoposide, and dexamethasone (16.17) .
UThe remaining four patients all received induction regimens that included daunorubicin and cytarabine.
flFive patients experienced leukemic relapse prior to a consolidation therapy phase and received reinduction therapy instead.
#Ten of these 12 patients had bone marrow specimens coincident with the achievement of first morphologic remission available for analysis, whereas the remaining two did not. cells not specifically meeting the above criteria were considered to be multidimensional flow cytometric negative. Investigators performed the multidimensional flow cytometnc analyses sequentially and were blinded with respect to corresponding pathologic or clinical data during this analysis phase. The diagnosis of AML and the remission classification of bone marrow aspirates were confirmed independently by an oncologist and a pathologist after review of a Wright-Giemsa-stained slide, enzyme histochemistry, and standard immunophenotype analysis performed initially at the institution where the patient was treated. Morphologic remission was defined as the presence of less than or equal to 5% blast cells by direct microscopic evaluation.
Statistical Analysis
The use of cryopreserved specimens for retrospective study restricted our ability to perform analyses at a common time point. Therefore, the patients were initially classified on the basis of leukemic cell detection, by means of multidimensional flow cytometric analysis, at the achievement of first morphologic remission to determine whether classification on the basis of a single specimen was associated with relapse. Thirty-five (90%) patients had a marrow specimen obtained at a time concurrent with the achievement of first morphologic remission. A case was considered multidimensional flow cytometric positive for this analysis if leukemia was detected in this specimen.
Since the multidimensional flow cytometric analyses were repeated a varying number of times and at different times for each patient, a time-varying Cox regression analysis (12) that controlled for sample time intervals, age, sex, FAB classification, and white blood cell (WBC) count at diagnosis was used to relate the risk of relapse after induction of remission to the multidimensional flow cytometric measurement. For this analysis, the multidimensional flow cytometric value was converted to either a 1 or 0 dichotomy (to reflect presence or absence of abnormal cells) or to three values, 0-2, coding for less than or equal to 0.1%, greater than 0.1% but less than 10%, and greater than or equal to 10% abnormal cells. The multidimensional flow cytometric value at any given day of follow-up was taken to be the most recently measured value (prior to that day). Thus, if a patient's multidimensional flow cytometric assay value changed from negative to positive, or vice versa, the most recent prior value would be considered constant (for the purpose of the Cox proportional hazards analysis) for each time interval studied. Note that differences in the risk of relapse reported for individuals with positive versus negative flow cytometric values reflect instantaneous differences rather than a cumulative nsk across varied time intervals between flow cytometric measurements. Only values measured after morphologic remission had been established (by light microscopy) and before any marrow relapses were included. All reported P values are two-sided.
Results
Study Population
Patients were selected for study if cryopreserved diagnostic and/or remission marrow samples had been previously stored and were available for a retrospective analysis of residual disease. Statistical comparison of demographic and clinical characteristics of the 39 patients in the analysis group who achieved morphologic remission and 586 similar AML patients enrolled in Childrens Cancer Group protocol 2891 for pediatric AML revealed no significant differences with regard to age (P = .09), FAB morphologic classification (P = .45), WBC count at diagnosis (P = .44), relapse rate (P = .25), overall survival (P = .98; logrank test), or event-free survival (/> = .78; logrank test). A significant difference was noted only for sex; males constituted 72% and 49% of the analysis group and the Childrens Cancer Group study population, respectively (P = .006). The cohort studied for the presence of residual leukemia was otherwise representative of the larger current treatment group as a whole.
Clinical Outcome
Twelve (31%) of the 39 patients were treated with an allogeneic bone marrow transplant during their first complete remission. Twenty-three (59%) of the patients experienced a leukemic relapse at a median time of 257 days after diagnosis (range, 48-863 days). Sixteen (41%) patients died at a median time of 481 days following diagnosis (range, 221-1339 days); 12 (75%) of these 16 patients died of recurrent leukemia, and the remaining four died of toxic effects associated with bone marrow transplantation. These causes included progressive bronchiolitis obliterans, severe acute graft-versus-host disease, acute encephalopathy of unknown etiology, and Epstein-Barr virus lymphoproliferative syndrome associated with immunosuppressive therapy. The median follow-up time for the remaining 23 living patients was 903 days (range, 150-2391 days).
Relationship of Leukemic Relapse Measured by Detection of Blast Cells With Aberrant Antigen Expression
Two investigators independently analyzed multidimensional flow cytometric list-mode data from numerically coded bone marrow specimens for evidence of residual leukemia. Reported flow cytometric results differed between the two investigators for five specimens, and the disputes were arbitrated by reanalyzing the list-mode data jointly. In all instances, consensus was achieved, although a third investigator was prepared to decide any remaining disputes after the joint listmode reanalysis. Investigators were limited to immunophenotypic data from the diagnostic and subsequent bone marrow specimens obtained at various intervals during therapy. Only after all specimens had been classified as multidimensional flow cytometric positive or negative were comparisons made between the patient's clinical course and flow cytometric values.
Detection of Leukemia at the Achievement of Morphologic Remission
Multidimensional flow cytometric analysis detected cells with an evaluable aberrant immunophenotype in all patients at diagnosis and in 19 (54%) of the 35 patients who had a marrow specimen obtained at the achievement of first morphologic remission that was available for analysis (Fig. 2) . Among these 19 multidimensional flow cytometric-positive patients, relapse occurred at a median time of 153 days after diagnosis (range, 48- Histograms E and F reflect marrow findings for this patient 119 days later, during morphologic remission. Notably, leukemic blast cells demonstrating an aberrant antigenic constellation are absent from the normal specimen (A and B), present at diagnosis in the patient with leukemia (C and D), and detectable at a level of 2% in this same patient in continued remission (E and F). Aberrant expression of a nonmyeloid antigen (i.e., CD7) is exhibited by leukemic blast cells in histograms D and F. In histograms A, C, and E, fluorescence intensity reflecting the differential expression of CD45 is plotted against side scatter. In each case, a computerized gate is drawn to limit further analysis to the group of cells (shown in red) with side scatter and CD45 expression distinctive of myeloblasts. This gate also serves to exclude dead cells, cellular debris, normal lymphocytes, monocytes. maturing myeloid elements, and normal lymphoblasts from further analysis. Histograms B, D, and F quantitatively display the fluorescence intensity from fluorescein isothiocyanate (HI C)-conjugated CD7 monoclonal antibodies (log scale) plotted against the fluorescence intensity from phycoerythrin (PE>conjugated CDS monoclonal antibodies (log scale) limited to the gate of events defined by the CD45/side-scatter gate.
863 days) in 13 (93%) of 14 who did not undergo allogeneic bone marrow transplantation. The 14th patient, a child with Down syndrome, remained alive and well without leukemic relapse at a follow-up time of 669 days.
Of the original 35 patients, 16 (46%) had no evidence of leukemia by multidimensional flow cytometric analysis at the achievement of morphologic remission. Among these 16 multidimensional flow cytometric-negative patients, relapse eventually occurred at a median time of 413 days following diagnosis (range, 321-794 days) in nine (82%) of 11 who did not undergo allogeneic bone marrow transplantation. This relapse proportion was not statistically different from that of patients classified as multidimensional flow cytometric positive at the achievement of first morphologic remission. However, the median time to relapse was 9 months later than that of the multidimensional flow cytometric-positive patient group.
Of the 10 individuals who were treated with allogeneic bone marrow transplants during their first complete remission (five multidimensional flow cytometric-positive and five multidimensional flow cytometric-negative patients), a single positive patient experienced a subsequent leukemic relapse at 265 days after diagnosis. Three of the 10 patients died of transplant-related toxic effects.
Detection of Leukemia From Multiple Samples Obtained Subsequent to the Achievement of Morphologic Remission
Since the multidimensional flow cytometric analyses were performed at different times following the achievement of morphologic remission for each patient, a time-varying Cox proportional hazards analysis that controlled for age, sex, FAB classification, and WBC count at diagnosis was used to relate the risk of relapse following the induction of remission to the multidimensional flow cytometric measurement. A total of 205 bone marrow specimens obtained at various intervals during therapy was available for study, and an average of 5.3 samples was evaluated for each patient. Since patients received heterogeneous consolidation therapies, all were initially included in the dataset, and those in whom an allogeneic bone marrow transplant was performed were censored at the date of the transplant. In a separate time-varying regression analysis, allogeneic bone marrow transplantation was included as a time-dependent covariate, and patients were not censored at the time of bone marrow transplantation.
In the first Cox regression analysis, multidimensional flow cytometric values of greater than 0.1% (multidimensional flow cytometric positive) were sig- nificantly related to the risk of leukemic relapse (P = .02; Table 3 ). During time periods of multidimensional flow cytometric positivity (an interval of morphologic remission when the immediately preceding measurement was positive), the patient's risk of relapse was estimated to be 2.8 times the risk during multidimensional flow cytometric-negative intervals (95% confidence interval [CI] = 1.1-7.0). Controlling the analysis for age, sex, FAB classification, and WBC count at diagnosis did not significantly affect this result. Hence, the detection of residual disease during remission was an independent adverse prognostic factor. A separate regression analysis that included allogeneic bone marrow transplantation as a time-dependent covariate demonstrated similar associations. When multidimensional flow cytometric results of more than 0.1% were separately coded as greater than 0.1% but less than 10% and greater than or equal to 10% abnormal, the corresponding risk estimates were 2.3 (95% CI = 0.9-6.3) and 4.5 (95% CI = 1.4-15.0), respectively, indicating a gradient in risk with higher 
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•Relative risks and 95% confidence intervals were estimated from the Cox proportional hazards model.
proportions of abnormal cells (P for trend = .01; Table 3 ). Similar relationships were demonstrated in an analysis that included allogeneic transplantation as a time-dependent covariate.
Immunophenotype of Residual Disease
In nine (41%) of 22 patients who experienced a leukemic relapse, a subpopulation of cells with an aberrant antigenic expression pattern that was different from that detected in the diagnostic specimen was identified by multidimensional flow cytometry. The most common motif was a change in the expression of one antigen that had previously been present or absent. In each of these instances, the qualitative and/or quantitative variation of aberrant antigen expression was readily identified in the follow-up bone marrow specimen.
Discussion
Despite aggressive induction chemotherapy, the majority of patients with AML experience leukemic relapses that cannot be predicted with current laboratory techniques. Multidimensional flow cytometry, a quantitative assay that permits the identification of rare residual leukemia cells during complete morphologic remission, was evaluated for its ability to accurately predict leukemic relapse in children treated for AML. Among patients who did not receive an allogeneic bone marrow transplant during their first complete remission, early marrow assessment with the multidimensional flow cytometric assay identified patients likely to experience relapse. With the exception of one child with Down syndrome, a characteristic known to be associated with an unusually low relapse frequency (75), every patient achieving morphologic remission in whom leukemic blast cells were detected by the assay subsequently experienced relapse.
Detection of leukemia with the multidimensional flow cytometric assay conferred a likelihood of leukemic relapse almost three times that experienced by patients in whom no leukemia was detected. The assay for cells demonstrating aberrant antigen expression was universally applicable in each instance of AML and sufficiently robust to detect cells with abnormal antigenic expression in cryopreserved specimens with a lower limit of detection of 10" 3 . Bone marrow specimens were analyzed rapidly with a flow cytometric assay that permitted the detection and characterization of unique combinations of antigens expressed by leukemic blast cells.
Although most patients lacking detectable leukemia at the achievement of morphologic remission eventually experienced a relapse, the median time to relapse was 9 months later than that of the multidimensional flow cytometricpositive patient group. The inability to predict relapse in these patients was probably due to the fact that aberrant cells were present at a level below the sensitivity of the flow cytometric technique. More frequent monitoring of patients during periods of morphologic remission might allow earlier identification of occult disease. Current ongoing studies seek to address this issue specifically.
A study of adult patients with AML has identified residual leukemia by abnormal expression patterns of normal hematopoietic antigens in remission bone marrow specimens. Reading et al. (9) reported findings from a cohort of 16 patients analyzed for residual leukemia at the attainment of morphologic remission. Patients positive for cells displaying an aberrant constellation of antigens experienced leukemic relapse at a significantly greater frequency than those without such cells. Our examination of a pediatric population demonstrated that the ratio of children with positive multidimensional flow cytometric values to those negative for abnormal cells by this technique at the achievement of morphologic remission is similar to that reported previously for adults.
Historically, the vast majority of adult patients with AML who achieve morphologic remission after treatment with induction chemotherapy alone subsequently experience relapse during the first year, suggesting that occult leukemic blast cells are not fully eradicated by use of this treatment approach (74). More recently, investigators have coupled induction chemotherapy with consolidation or intensification regimens, with the intent of eliminating residual disease (75-77). In each of these treatment protocols, however, further aggressive therapy was justifiably applied to the entire study population because an individual patient's risk of relapse was impossible to ascertain. Inevitably, some patients who were unlikely to relapse sustained substantial exposure to unnecessary therapy. By use of the multidimensional flow cytometric assay, patient stratification to various therapeutic approaches could be based on a patient's response to therapy rather than his/her initial presentation parameters.
In this retrospective analysis of 39 children treated for AML, detection of leukemic cells during first remission imparted an approximately threefold greater risk of subsequent relapse. Further studies evaluating larger cohorts of patients are necessary, however, to confirm these findings. To identify patients in early relapse and to allow for prompt therapeutic intervention, such studies should endeavor to determine the optimum frequency and timing of monitoring. In conjunction with a new AML treatment protocol, the Childrens Cancer Group has initiated a prospective, multicenter investigation to confirm the hypothesis that patients harboring identifiable residual leukemic cells during morphologic remission are likely to experience a more rapid leukemic relapse.
